Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Oct 15, 2009

Premium

Title: Compositions and Processes Using siRNA, Amphipathic Compounds, and Polycations

Number: 7,601,367

Filed: May 14, 2004

Lead Inventor: Sean Monahan, Mirus Bio (Roche)

The patent, its abstract states, claims "a deliverable composition with low toxicity comprising an amphipathic compound, a polycation, and a siRNA. The composition may be used in the process of delivering a siRNA to an animal cell or more particularly, a mammal cell."


Title: Means for Inhibiting the Expression of CD31

Number: 20090252783

Filed: April 20, 2007 PCT Filed: April 20, 2007

Lead Inventor: Jorg Kaufman, Silence Therapeutics

The invention relates to a double-stranded nucleic acid molecule, according to the patent application's abstract.

The first strand contains two stretches of contiguous nucleotides, with one stretch at least partially complementary to a target nucleic acid and the second stretch at least partially complementary to the first stretch, it adds. The first stretch of nucleotides is also "at least partially complementary to a region preceding the 5' end of [a defined] nucleotide core sequence and/or to a region following the 3' end of [a defined] nucleotide core sequence.


Title: Compositions Comprising Inhibitors of RNA-Binding Proteins and Methods of Producing and Using the Same

Number: 20090252784

Filed: April 20, 2009

Lead Inventor: Courtney Houchen, University of Oklahoma Health Sciences Center

The invention, the patent application's abstract states, comprises "compositions for inhibiting RNA binding proteins, as well as methods of producing and using the same."

The application specifically claims an siRNA that can silence RNA binding motif protein 3 expression.


Title: Inhibitors of Mammalian HDAC 11 Useful for Treating HDAC 11-Mediated Disorders

Number: 20090253769

Filed: Jan. 18, 2005 PCT Filed: Jan. 18, 2005

Lead Inventor: Gessica Filocamo, Merck

The invention, the patent application's abstract states, "relies, in part, on the discovery of the role of HDAC 11 in various cell proliferative disorders including cancer." It also claims "methods of inhibiting HDAC 11 as a means of treating cell proliferative disorders," as well as "reagents for use in inhibiting human HDAC 11."

The application specifically claims an siRNA that down-regulates expression of mammalian HDAC 11 through RNAi.


Title: Target Gene Mimitin of Myc

Number: 20090253770

Filed: May 17, 2005 PCT Filed: May 17, 2005

Inventor: Makoto Tsuneoka, Kurume University

The patent application claims "a new diagnosis or treatment of cancer, "comprising the "protein mimitin which is a target of a cancer gene myc protein, a variant thereof and a fragment thereof, [and] a polynucleotide molecule encoding them." The invention also comprises "an inhibitory substance of biological activity … afforded by the binding of a polynucleotide molecule encoding a mimitin protein and myc, [which] provides a useful means for the diagnosis, prophylaxis, or treatment of cancer."


Title: RNA Interference-Mediated Inhibition of CXCR4 Gene Expression Using Short Interfering Nucleic Acid

Number: 20090253772

Filed: Dec. 12, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention "relates to compounds, compositions, and methods useful for modulating chemokine receptor gene expression using short interfering nucleic acid molecules," the patent application's abstract states. It also relates to "compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CXCR gene expression and/or activity by RNA interference using small nucleic acid molecules," including siRNAs, and methods used to modulate CXCR genes such as CXCR4 and CXCR7A.


Title: RNA Interference-Mediated Inhibition of TNF and TNF Receptor Gene Expression Using Short Interfering RNA

Number: 20090253773

Filed: Dec. 12, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and/or tumor necrosis factor receptor gene expression using short interfering nucleic acid molecules," as well as "compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of tumor necrosis factor and/or tumor necrosis factor receptor gene expression and/or activity by RNA interference using small nucleic acid molecules."

The invention specifically comprises "small nucleic acid molecules … and methods used to modulate the expression of tumor necrosis factor and/or tumor necrosis factor receptor genes."


Title: RNA Interference-Mediated Inhibition of Platelet-Derived Growth Factor and Platelet-Derived Growth Factor Receptor Gene Expression Using Short Interfering RNA

Number: 20090253774

Filed: Dec. 12, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention relates to "compounds, compositions, and methods useful for modulating platelet derived growth factor and/or platelet-derived growth factor receptor gene expression using short interfering nucleic acid molecules," the patent application's abstract states, as well as "compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of platelet-derived growth factor and/or platelet-derived growth factor receptor gene expression and/or activity by RNA interference using small nucleic acid molecules.

"In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of platelet derived growth factor and/or platelet-derived growth factor receptor genes," the abstract adds.


Title: siRNA Targeting Gremlin

Number: 20090253776

Filed: May 28, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CKSF1B1."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.